PE20141479A1 - Senuelos humanos notch1 - Google Patents

Senuelos humanos notch1

Info

Publication number
PE20141479A1
PE20141479A1 PE2014000473A PE2014000473A PE20141479A1 PE 20141479 A1 PE20141479 A1 PE 20141479A1 PE 2014000473 A PE2014000473 A PE 2014000473A PE 2014000473 A PE2014000473 A PE 2014000473A PE 20141479 A1 PE20141479 A1 PE 20141479A1
Authority
PE
Peru
Prior art keywords
human
sequence
fusion protein
amino acids
notch1
Prior art date
Application number
PE2014000473A
Other languages
English (en)
Inventor
Jan Kitajewski
Carrie Shawber
Thaned Kangsamaksin
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48044136&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141479(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Columbia filed Critical Univ Columbia
Publication of PE20141479A1 publication Critical patent/PE20141479A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA PROTEINA DE FUSION QUE COMPRENDE LA SECUENCIA DE LA CUAL AMINOACIDOS CONSECUTIVOS, COMENZANDO EN EL EXTREMO N-TERMINAL DE LA PROTEINA DE FUSION, ES IDENTICA A LA SECUENCIA DE AMINOACIDOS EN: A) UN DOMINIO EXTRACELULAR DE UNA PROTEINA DE RECEPTOR NOTCH1 HUMANO; SEGUIDO POR B) UNA PORCION FC DE UN ANTICUERPO; EN DONDE EL DOMINIO EXTRACELULAR DE LA PROTEINA HUMANA DEL RECEPTOR NOTCH1 i) COMIENZA CON EL AMINOACIDO PRESENTE EN EL EXTREMO N-TERMINAL DE LA REPETICION TIPO EGF 10, Y ii) SE EXTIENDE AL MENOS A TRAVES DEL AMINOACIDO EN EL C-TERMINAL DE REPETICION TIPO EGF 23. DICHA SECUENCIA DE AMINOACIDOS CONSECUTIVOS DE LA PROTEINA DE FUSION COMPRENDE LA SECUENCIA DE SEQ ID N�: 3 O 5. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA PARA INHIBIR LA ACTIVIDAD DE JAGGED-1 SIENDO UTIL EN EL TRATAMIENTO DE DEGENERACION MACULAR RELACIONADA CON LA EDAD, RETINOPATIA DIABETICA, CANCER
PE2014000473A 2011-10-04 2012-10-04 Senuelos humanos notch1 PE20141479A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161543186P 2011-10-04 2011-10-04

Publications (1)

Publication Number Publication Date
PE20141479A1 true PE20141479A1 (es) 2014-11-05

Family

ID=48044136

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014000473A PE20141479A1 (es) 2011-10-04 2012-10-04 Senuelos humanos notch1

Country Status (19)

Country Link
US (2) US9738708B2 (es)
EP (1) EP2763700A4 (es)
JP (1) JP2014532061A (es)
KR (1) KR20140093942A (es)
CN (1) CN103917247A (es)
AR (1) AR088048A1 (es)
AU (1) AU2012318664A1 (es)
BR (1) BR112014008025A2 (es)
CA (1) CA2850944A1 (es)
CL (1) CL2014000852A1 (es)
HK (1) HK1198427A1 (es)
IL (1) IL231920A0 (es)
MX (1) MX2014004132A (es)
PE (1) PE20141479A1 (es)
RU (1) RU2014117160A (es)
SG (1) SG11201401186RA (es)
TW (1) TW201329105A (es)
WO (1) WO2013052607A1 (es)
ZA (1) ZA201403044B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005111072A2 (en) * 2004-04-29 2005-11-24 The Trustees Of Columbia University In The City Of New York Notch-based fusion proteins and uses thereof
NZ600171A (en) * 2007-08-23 2014-01-31 Univ Columbia Compositions of humanized notch fusion proteins and methods of treatment
KR20110074846A (ko) 2008-08-22 2011-07-04 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 노치３ 신호전달의 디코이 억제제로서의 인간 노치３ 기반 융합 단백질
AR088048A1 (es) * 2011-10-04 2014-05-07 Univ Columbia Señuelos notch1 humanos
CN105585636B (zh) * 2015-11-24 2020-03-03 南方医科大学 一种人NOTCH1 NICD蛋白Ser2162位点磷酸化抗体及其制备方法和应用
US11026996B2 (en) 2016-05-25 2021-06-08 The Trustees Of Columbia University In The City Of New York Human Notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and DLL-notch signaling
WO2023192802A1 (en) * 2022-04-01 2023-10-05 The Board Of Trustees Of The University Of Illinois Notch1 and notch4 decoys and methods of use

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
IE20030749A1 (en) * 1991-05-03 2003-11-12 Indiana University Foundation Human notch and delta binding domains in torporythmic proteins, and methods based thereon
US6716974B1 (en) 1996-05-31 2004-04-06 Maine Medical Center Research Institute Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids
FR2751986B1 (fr) 1996-08-01 1998-12-31 Inst Nat Sante Rech Med Gene implique dans le cadasil, methode de diagnostic et application therapeutique
US6379925B1 (en) * 1997-06-18 2002-04-30 The Trustees Of Columbia University In The City Of New York Angiogenic modulation by notch signal transduction
US6703221B1 (en) 1999-08-19 2004-03-09 Chiron Corporation Notch receptor ligands and uses thereof
GB9927328D0 (en) 1999-11-18 2000-01-12 Lorantis Ltd Immunotherapy
US6689744B2 (en) 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses
JP2005526701A (ja) 2001-11-14 2005-09-08 ロランティス リミテッド 内科療法
WO2003087159A2 (en) 2002-04-05 2003-10-23 Lorantis Limited Modulators of the notch signalling pathway and uses thereof in medical treatment
JP2006513260A (ja) 2002-08-03 2006-04-20 ロランティス リミテッド Ｎｏｔｃｈシグナル伝達経路調節因子の複合体およびその薬物治療への使用
AU2003267563A1 (en) 2002-09-10 2004-04-30 Lorantis Limited Pharmaceutical composition and medical treatments comprising notch ligand proteins
WO2005111072A2 (en) 2004-04-29 2005-11-24 The Trustees Of Columbia University In The City Of New York Notch-based fusion proteins and uses thereof
US20060134121A1 (en) 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
WO2006047878A1 (en) 2004-11-03 2006-05-11 British Columbia Cancer Agency Branch Cancer therapeutics and methods for their use
WO2007016419A2 (en) 2005-07-29 2007-02-08 The General Hospital Corporation Methods and compositions for reducing skin damage
WO2008051797A2 (en) 2006-10-19 2008-05-02 Genentech, Inc. Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
EP2125887A4 (en) * 2007-01-24 2010-11-10 Oncomed Pharm Inc COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF CANCER
NZ600171A (en) 2007-08-23 2014-01-31 Univ Columbia Compositions of humanized notch fusion proteins and methods of treatment
EP2899211A1 (en) * 2008-07-08 2015-07-29 OncoMed Pharmaceuticals, Inc. Notch1 receptor binding agents and methods of use thereof
KR20110074846A (ko) 2008-08-22 2011-07-04 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 노치３ 신호전달의 디코이 억제제로서의 인간 노치３ 기반 융합 단백질
AR088048A1 (es) * 2011-10-04 2014-05-07 Univ Columbia Señuelos notch1 humanos

Also Published As

Publication number Publication date
KR20140093942A (ko) 2014-07-29
CL2014000852A1 (es) 2014-12-12
WO2013052607A1 (en) 2013-04-11
AU2012318664A1 (en) 2014-05-22
US20140271643A1 (en) 2014-09-18
EP2763700A1 (en) 2014-08-13
US10227399B2 (en) 2019-03-12
WO2013052607A9 (en) 2014-04-10
JP2014532061A (ja) 2014-12-04
MX2014004132A (es) 2014-07-24
US9738708B2 (en) 2017-08-22
BR112014008025A2 (pt) 2017-04-11
IL231920A0 (en) 2014-05-28
ZA201403044B (en) 2016-01-27
SG11201401186RA (en) 2014-04-28
HK1198427A1 (en) 2015-04-24
CA2850944A1 (en) 2013-04-11
CN103917247A (zh) 2014-07-09
RU2014117160A (ru) 2015-11-10
TW201329105A (zh) 2013-07-16
AR088048A1 (es) 2014-05-07
US20170306006A1 (en) 2017-10-26
EP2763700A4 (en) 2015-05-27

Similar Documents

Publication Publication Date Title
PE20141479A1 (es) Senuelos humanos notch1
CL2017002761A1 (es) Proteínas de fusión
CO6220870A2 (es) Prediccion de respuesta a un inhibidor a un inhibidor de dimerizacion her basado en expresion de her3 bajo
PE20141561A1 (es) Anticuerpos anti-lrp5 y metodos de uso
AR079333A1 (es) Anticuerpos contra csf -1r humano y usos de los mimos
PE20120532A1 (es) ANTICUERPOS ANTI-ActRIIB
PE20141546A1 (es) Anticuerpos anti-cd134(ox40) y sus usos de los mismos
ES2676499T3 (es) Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones
UY33204A (es) Metodos y composiciones usando polipeptidos de fusion de fgf23
PE20171058A1 (es) Composiciones y metodos de uso para tratar trastornos metabolicos
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
BR112015022978A8 (pt) tecnologias de multimerização
PE20141659A1 (es) Dominios variables singulares anti-vgf fusionados con dominios de fc
CU20140034A7 (es) Proteínas de fusión para tratar trastornos metabólicos
BR112013032717A2 (pt) coagonistas do receptor de glucagon/glp-1
PE20130199A1 (es) Proteina de fusion robo1-fc y su utilizacion en el tratamiento de tumores
BR112014026740A2 (pt) anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
ES2633597T3 (es) Anticuerpos con afinidad modificada para FcRn que promueven la eliminación del antígeno
PE20190743A1 (es) Metodos para el tratamiento de la atrofia muscular y enfermedad osea con el uso de proteinas trap hibridas novedosas del ligando actriib
CY1119149T1 (el) Αντικαρκινικη πρωτεϊνη συντηξης
EA201490790A1 (ru) Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1
PH12015500480B1 (en) Antibody formulations and uses thereof
GT201700224A (es) Proteína de unión a rgma y su uso
PE20170142A1 (es) Proteina de fusion que inhibe angiogenesis o crecimiento y uso de la misma
PE20141158A1 (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapeutico

Legal Events

Date Code Title Description
FD Application declared void or lapsed